Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis
| Autor: | Charles J. Schneider, Robert L Witt, Adam Raben, Alexandra L. Hanlon, Elizabeth Mauer, Neil Hockstein, Joshua D. Palmer, Michael Dzeda, Jordan S. L. Silberg, Jon Strasser |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Skin Neoplasms medicine.medical_treatment Cetuximab Cohort Studies 030207 dermatology & venereal diseases 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Internal medicine medicine Humans Progression-free survival Head and neck neoplasms Aged Aged 80 and over Postoperative Care Squamous Cell Carcinoma of Head and Neck business.industry Chemoradiotherapy Middle Aged Survival Analysis digestive system diseases Post operative radiotherapy Radiation therapy Tolerability 030220 oncology & carcinogenesis Toxicity Propensity score matching Female Neoplasm Recurrence Local Oral Surgery business medicine.drug |
| Zdroj: | Oral Oncology. 78:102-107 |
| ISSN: | 1368-8375 |
| Popis: | Objectives The objective of this study was to investigate the safety, tolerability and preliminary efficacy of radiotherapy plus cetuximab in high risk CSCC patients. Materials and Methods Patients with high-risk CSCC diagnosed between 2006 and 2013 were analyzed. Patients were divided into two groups: radiotherapy alone versus radiotherapy plus cetuximab. Among 68 patients meeting study criteria, we identified 29 treated with cetuximab plus RT and 39 with RT alone. Primary analysis examined disease-free and overall survival, freedom from local and distant recurrence in the propensity score matched cohort. Propensity score analysis was performed with weighted factors including: Charlson Comorbidity Index score, age. KPS, primary location, T and N stage, recurrent status, margin status, LVSI, PNI and grade. Toxicity was assessed using the CTCAE v4.0. Results Median follow-up for living patients was 30 months. Patients in the cetuximab group were more likely to have advanced N stage, positive margins and recurrent disease. After propensity score matching the groups were well balanced. Six patients experienced ≥ grade 3 acute toxicity in the cetuximab group. The 1-year, 2-year and 5-year progression free survival (PFS) for patients in the cetuximab group were 86%, 72% and 66%, respectively. The 1-year, 2-year and 5-year overall survival (OS) for patients in the cetuximab group was 98%, 80% and 80%, respectively. Conclusions Although limited by small numbers, the combination of cetuximab and radiotherapy in CSCC appears well tolerated there were more long-term survivors and less distant metastasis in the cetuximab group. These promising finding warrant further studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect